Klotho Neurosciences seeking to expand into adjacent technologies

Klotho Neurosciences (KLTO)announced that it is evaluating the acquisition of “several complementary technologies” aimed at supporting healthy brain function, organ health, and longevity. “In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer’s, and Parkinson’s, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases-ultimately promoting a longer, healthier life,” the company stated. “As announced previously, we’ve begun manufacturing and clinical development of KLTO-101 and KLTO-202. We’re also exploring other treatments that could support healthy aging and extend human longevity,” said Klotho CEO Dr. Joseph Sinkule.